




已閱讀5頁(yè),還剩34頁(yè)未讀, 繼續(xù)免費(fèi)閱讀
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Concerns from Data Analysis in the Real-World Shengshou Hu M.D., FACC Department of Cardiac Surgery Fu Wai Hospital, Beijing, China DES 2007 UPDATE Textbook & Theory Drug-eluting Stents Drug based therapeutics Bare-metal Stents Evolution of Cardiology The Era of Drug-eluting Stents More CAD patients prefer DES I prefer a less invasive and more comfortable therapy The Era of Drug-eluting Stents In the praise of DES, controversies never stop The Era of Drug-eluting Stents Safety and effectiveness: Remained unanswered DES vs. BMS: Different results from different RCTs DES vs. CABG: 3 RCTs are ongoing Editorials in NEJM on safety and efficacy of DES The Era of Drug-eluting Stents Restate the indication for DES CYPHER: target lesion 30 mm TAXUS: target lesion 28 mm The Era of Drug-eluting Stents What is the current status of DES in the real-world? The Era of Drug-eluting Stents Too perfect designed to consider the difference among hospitals, physicians Enrolled patients are relative healthier and exclude patients at high risk Selection bias and uncontrolled, but can reflex the truth in the real-world The Era of Drug-eluting Stents DES in The Real-world DES in The Real-world DES in The Real-world DES in The Real-world A revolution brought by DES ? DES seems to be an optimal choice * DES reduces rate of stent restenosis compared with BMS. * How much will DES benefit patients in the real-world? * Can DES maintain its advantage compared with bypass in the real-world? DES in The Real-world Data analysis from New York State Registry Database DES in The Real-world TRIAL DESIGN Patients Statistical Analysis 17400 multi-vessel patients DES n=9,963 (at least one DES) CABG n=7,437 Follow-up achieved in 99.0% 18 months 1) Propensity Analysis 2) Kaplan-Meier method 3) Cox proportional hazards models DES in The Real-world DES: 18-mth rate of revascularization 30% DES in The Real-world 18-mth Survival Analysis CABG is superior to DES in term of Total Mortality DES in The Real-world 18-mth Survival Analysis for MI CABG is superior to DES in term of Myocardial Infarction DES in The Real-world Subgroup Analysis DES in The Real-world CABG remains the standard of care for patients who require multivessel coronary revascularization. However, stents may be an alternative for patients at high risk for surgical complications or when an informed patient chooses a less invasive option. DES in The Real-world We would like to have used a longer follow-up period. Nevertheless, it would appear that the advantage of CABG would have persisted over the course of another year or two of follow-up, because our evidence of that tendency and because there is evidence of very late stent thrombosis in patients receiving DES. DES in The Real-world 010002000300040005000600070008000外科手術(shù)2002年 2003年 2004年2005年 2006年 2007年0200040006000800010000院所2 0 0 5 至2 0 0 7 年心臟介入量2005年 2006年 2007年010002000300040005000600070008000外科手術(shù)2002年 2003年 2004年2005年 2006年 2007年Data analysis from Fuwai Hospital Registry Database Surgical volume by year PCI volume by year CABG Database: over 6000 cases Stent Database: over 7000 cases DES in The Real-world TRIAL DESIGN Patients ( 20042005) Statistical Analysis 3709 multi-vessel patients CABG (n=1875) DES (n=1834) Follow-up achieved in 98.0% 22.2 9.8 months Propensity Analysis Kaplan-Meier method Cox proportional hazards models Outcome measures Total mortality Repeated revascularization Target-vessel revascularization Q-wave myocardial Infarction Data analysis from Fuwai Hospital Registry Database DES in The Real-world DES in The Real-world Cumulative event rates during follow-up period DES in The Real-world Survival Analysis for Total Mortality DES in The Real-world Survival Analysis for Revascularization DES in The Real-world Logrank P 0.0001 Survival Analysis for TVR DES in The Real-world Survival Analysis for Q-wave MI DES in The Real-world Favors CABG Favors DES Subgroup Analysis: Cox model with PS stratification DES in The Real-world Conclusions DES in The Real-world CABG Patients were sicker Being older More co-morbidities Poorer LV function DES patients had higher rates of adverse outcomes Total mortality Revascularization TVR Q-wave MI Discussion and Comment What is the Differences between Bypass and PCI PCI is targeted at the “culprit” lesion or lesions. CABG is directed at the vessel including lesions and future culprits. March 2005 LIMAThe Golden Standard for LAD 10年通暢率 95% 15年通暢率 94 相當(dāng)于 DES 1年通暢率 Tatoulis JTCVS,2004 Discussion and Comment CABG, the standard method for coronary revascularization Fuwai Database Discussion and Comment 0.6% Mortality Bypass surgery On-pump CABG Off-pump technique Mimi-incision Port-access Fast tract anesthesia Less Invasive Excellent perioperative outcomes Satisfactory long-term benefits Becoming less invasive The safety and effectiveness confirmed by 30 years of experiences Concerns on DES appear Discussion and Comment Does DES bring a fundamental revolution to the PCI? Reduce the rate of stent restenosis Lead to early and very late stent thrombosis Intensive post-DES anticoagulation bring new complications Safety requiring longer-term follow-up Discussion and Comment Cover of LANCET Jan 2006 Why so many CABG indicated patients receive PCI at last? In the real-world, do CAD pati
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 股權(quán)質(zhì)押合同中免責(zé)條款
- 稀土金屬礦床開(kāi)采的礦區(qū)文化建設(shè)與傳承考核試卷
- 窄軌機(jī)車(chē)車(chē)輛制造過(guò)程中的品質(zhì)監(jiān)控考核試卷
- 智能護(hù)眼臺(tái)燈產(chǎn)品對(duì)比與評(píng)估考核試卷
- 稀土金屬在光電子學(xué)中的應(yīng)用考核試卷
- 少年宮主持人培訓(xùn)課程
- 糕點(diǎn)烘焙工藝優(yōu)化考核試卷
- 空中交通管制員航空器飛行特性考核試卷
- 綠色金融產(chǎn)品的設(shè)計(jì)與投資考核試卷
- 胃息肉護(hù)理查房
- 第18課《井岡翠竹》課件-2024-2025學(xué)年統(tǒng)編版語(yǔ)文七年級(jí)下冊(cè)
- 公立醫(yī)院成本核算指導(dǎo)手冊(cè)
- MOOC 中醫(yī)與辨證-暨南大學(xué) 中國(guó)大學(xué)慕課答案
- 年產(chǎn)10噸功能益生菌凍干粉的工廠設(shè)計(jì)改
- 三年級(jí)上冊(cè)語(yǔ)文閱讀同步擴(kuò)展課件-第十五講 童話寓言的閱讀技巧(共14張PPT)-人教(部編版)
- 機(jī)油濾清器工作原理剖析
- 執(zhí)行異議及復(fù)議課件
- 安全生產(chǎn)管理組織機(jī)構(gòu)設(shè)置圖
- 智能健身鏡行業(yè)分析及案例
- 中聯(lián)HIS系統(tǒng)掛號(hào)收費(fèi) 操 作 說(shuō) 明
- HIT(肝素誘導(dǎo)的血小板減少癥)課件
評(píng)論
0/150
提交評(píng)論